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Oral contraceptive pills were first introduced in the USA in 1960 and in the UK soon afterwards. Use increased
rapidly in the UK until the mid 1970s but declined thereafter. Initially oral contraceptives were used mainly for
family spacing by mature women and early studies ofpossible side-effects were confined to such women. The results
of these studies in respect of breast cancer risk were generally reassuring (see reviews by Kalache et al. (1983) and
Clavel et al. (1985)) as are recent reports from the two UK cohort studies (Kay & Hannaford, 1988; Vessey et al.,
1989) and the American Nurses Study (Lipnick et al., 1986). In fact no study to date has suggested any increased
risk of breast cancer in those generations of women exposed to oral contraceptives only during their middle
reproductive years.
In the early 1980s two reports from Southern California (Pike et al., 1981, 1983) suggested an increased risk of
breast cancer in young women associated with oral contraceptive use either before first full-term pregnancy or before
age 25. Subsequently, a number of other case-control studies have included women young enough to have been
exposed to oral contraceptives during their late teenage years and early 20s (see Table I), and the limited data on
young women from the cohort studies have been re-examined. Until very recently there appeared to be considerable
disagreement between different authors regarding the possible association between use of oral contraceptives and
breast cancer risk in young women. We shall discuss here some of the issues involved in interpretation of data from
case-control studies that could have contributed to the apparently inconsistent results.
Design and analysis of case-control studies
Case-control studies may be either hospital based or population based. In hospital based studies eligible cases are
identified from specific hospitals, whereas in population based studies all cases resident in a defined area are
ascertained (using a cancer registration or similar system). A control series for a hospital based study usually consists
ofhospital patients admitted with conditions thought to be unrelated to the disease or exposure of interest, whereas
that for a population based study should be drawn from the general population in the same area as that from which
the cases were drawn. Control series should be representative of the general population and while series of older
hospital controls may be representative, series of younger hospital patients may well not be. For studies ofdisease in
the young, therefore, population based case-control studies are to be preferred and five such studies have so far
been carried out (Pike et al., 1983; Stadel et al., 1985; Paul et al., 1986; Meirik et al., 1986; UK National
Case-Control Study Group, 1989).
Considerable practical difficulties can arise both in case ascertainment and in locating a control group in
population based studies. Cancer registration is mandatory in some countries (for example Norway and Sweden) so
that population based case series are virtually complete, but where registration is voluntary (as in the UK) delays in
notification and incompleteness of the register may occur and supplementary sources of information such as hospital
treatment or admission registers may have to be used. Delay in identification inevitably leads to a loss of cases of
advanced disease due to their early death. This -may lead to biased.results ;if survival isrelated. to oral contraceptive
use as has been suggested in some, but not all, studies (Matthews et al., 1981; Millard, et al., 1987). Selection of
population based controls presents few problems where a population register is available as in Norway and Sweden
(Meirik et al., 1986) but recourse to other selection procedures is necessary elsewhere: the UK National
Case-Control Study Group (1989) selected a control for each case from the list of the same general practitioner; in
the Cancer and Steroid Hormone (CASH) Study (Stadel et al., 1985) random digit dialling was used; Pike et al.
(1981, 1983) selected a neighbourhood control for each case by sampling dwellings; and Paul et al. (1986) sampled
from electoral rolls.
Information about oral contraceptive use and other risk factors for breast cancer is usually obtained by interview.
Interviews can be carried out face to face or by telephone. Telephone interviewing was used by Pike et al. (1981,
1983) and Paul et al. (1986). Most recent studies have used aids to recall, such as a calendar of life events and
photographs of the packaging of brands of oral contraceptives, both of which have been shown to improve accuracy
of recall (Coulter et al., 1986). These cannot be used directly in telephone interviews although Paul et al. (1986) sent
the life events calendar to their interviewees before interview.
In addition to contraceptive history, information regarding other possible confounding factors is collected at
interview. Confounding factors are associated independently with both disease and exposure and have the effect of
distorting the association between them. Examples in the context of oral contraceptives and breast cancer would be
age, menstrual history and obstetric history. Age is a strong potential confounder of the association between oral
contraceptive use and breast cancer risk because it is closely associated not only with the likelihood, duration and
pattern of oral contraceptive use, which changed very rapidly over a short period oftime, but also with breast cancer
risk, which increases sharply with age. Some authors have chosen to control for age by individual matching of
controls to cases by date of birth (Pike et al., 1981, 1983; Vessey et al., 1982, 1983; Miller et al., 1986; Meirik et al., 1986; McPherson et al., 1987; Jick et al., 1989; UK National Case-Control Study Group, 1989), while others have
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formally or informally frequency matched the case and control age distributions (Rosenberg et al., 1984; Stadel et
al., 1985; Paul et al., 1986; Miller et al., 1989; WHO, 1989) and subsequently controlled for age during analysis.
However, matching or stratification has not always been performed within narrow age bands, only two studies
having employed very close individual matching on age (Meirik et al., 1986; UK National Case-Control Study
Group, 1989) and both of these report a positive association between total oral contraceptive use and breast cancer
risk. Five-year age groups have been more commonly used (Pike et al., 1981, 1983; Vessey et al., 1982, 1983; Stadel
et al., 1985; Paul et al., 1986; McPherson et al., 1987). It is possible that matching or adjustment in 5-year age
groups is inadequate, and Pike and Bernstein (1989) have suggested that single years of age should be used.
Bias
The major criticism of case-control studies is the potential for bias; the main potential biases in studies of oral
contraceptives and breast cancer have been reviewed by Skegg (1988). These are: non-response bias, recall bias,
interviewer bias and surveillance bias. We shall discuss each type of bias in the context of the published studies.
Hospital based case-control studies generally have much higher response rates from both cases and controls than
do population based studies because the respondents in the former are essentially 'captive', but this advantage must
be offset against the problems with control group selection described above. In the population based studies case
non-response rates varied between 11 and 44%. Sources of non-response include death of the patient before
interview, refusal by her doctor and moving away, as well as actual refusal to participate. Reported control
non-response rates vary between 11 and 24%. The control non-response rate in the CASH study (Stadel et al., 1985)
cannot be ascertained directly, although in a study of Wilm's tumour also using random digit dialling the overall
non-response rate was estimated to be in excess of 45% (Bunin et al., 1987). The validity of random digit dialling as
a method of control selection is becoming increasingly difficult to assess as the screening of telephone calls by
answering machines increases. However, where population registers or other simpler methods are not readily
available, alternative methods of assembling a control group may be both costly and difficult.
Only the UK National Case-Control Study Group (1989) and Meirik-et al. (1986) have attempted to assess the
magnitude of non-response and other biases. The UK National Case-Control Study Group (1989) found (by
abstracting general practitioner notes) some evidence of differences in oral contraceptive use between interviewed and
non-interviewed cases and that, as a result, relative risks for moderate durations of oral contraceptive use might have
been slightly exaggerated. Meirik et al. (1986) completed short telephone or postal questionnaires on oral contraceptive
use for about 50% of the non-responding controls in their study. They found that there were more 'never-users' among
non-responding than among interviewed controls, which may have led to some underestimation of their relative risks.
Interviewer and recall bias arise, the former because the interviewer unconsciously interviews cases more intensively
than controls and the latter because cases have cause to 'remember' better than controls. Media attention to the issue
under study makes recall bias plausible. Interviewer bias can be reduced by using highly structured interviews and careful
training but is best avoided by keeping the interviewers 'blind' to case or control status. In practice this 'blindness' is
exceedingly difficult and may be impossible to attain. Data from the UK National Study (1989) suggest that with careful
interviewing these biases are small.
Surveillance bias arises when the diagnosis ofbreast cancer is brought forward in oral contraceptive users due to an
increased frequency ofbreastexaminationintheuserscompared tonon-users. Frequentsurveillancemaythusproducean
apparentexcess ofcaseswho haveused oralcontraceptives, and henceanapparent increaseinrelativerisk. Thereisample
evidence that oral contraceptive users have more breast examinations than non-users and that they have been taught, or
practice, breast self-examination more frequently (Mant et al., 1987;.UK National Case-Control Study Group, 1989).
Skegg(1988)hascalculated thatifbreastcancerisdiagnosed 1 yearearlierinoralcontraceptive usersthannon-users, and
under theassumption thatoral contraceptive useandbreastcancerriskareunrelated, aspuriousrelativeriskof1.2would
result. However, the UK data (UK National Case-Control Study Group, 1989) suggest that diagnosis was advanced by
surveillance by only 0.17 years and that this would lead to a relative risk of only 1.03 in the absence ofany real effect.
A slightly different type of bias has been discussed by McPherson et al. (1986). A long latent period between
exposure to a carcinogen and the development ofcancer is common. Latency has been suggested as a possible reason
for inconsistences in the results of studies of oral contraceptives and breast cancer because patterns of oral
contraceptive use have varied over time and in different countries. Analyses to look for evidence of a latent effect
using McPherson et al.'s (1986) method have been carried out in the most recent studies (McPherson et al., 1987;
UK National Case-Control Study Group, 1989) but the evidence is at present inconclusive.
Summary of results
Table I summarises the results of recent studies that have included young women. Studies from the same investigators
using similar methods are grouped together. The relative risks given are those for the longest duration ofuse group and
significant trends in relative risk are indicated. While some authors have reported no significant increases in riskofbreast
cancer associated with oral contraceptive use (Vessey et al., 1982, 1983; Stadel etal., 1985; Miller etal., 1986; Paul etal.,
1986; Jick etal., 1989), othershavesuggested thepresence ofanincreased risk; no studyshows anyevidenceofaprotective
effect.
In both of Pike et al.'s (1981, 1983) studies there was a significant trend in relative risks with duration of total oral
contraceptive use; in the 1981 study this effect was explained by use before first full-termpregnancy and in the 1983 study
by use before age 25. The cases included in the first study were included in the second also, so that the interpretation of
these two studies presents some problems. Two other studies have found an effect of use only before first full-term
pregnancy (McPherson et al., 1987; Stadel et al., 1989). McPherson et al. (1987) used the same methodology as in an
earlier study in London and Oxford (Vessey et al., 1983) which found no evidence of any effect. However, as McPherson
et al.(1987) have pointed out, only 13% ofyoung women included in the earlier study (covering the years 1968-80) had
ever used oral contraceptives before their first pregnancy compared to over 40% in the later study. The recent re-analysis
by Peto (1989) of data included in a subset analysis of the CASH study (Stadel et al., 1988) has suggested that their data
do show an increased risk for use before first full-termpregnancy; this was recently confirmed by Stadel et al. (1989).
Studies showing an increased risk associated with total use at any time are those of Meirik et al. (1986) and the UKORAL CONTRACEPTIVES AND BREAST CANCER 3
Table I Case-control studies of oral contraceptives and breast cancer in young women
Hospitall Subgroup or
population Age No. of Relative longest duration
Authors Years based Country group cases rise ofuse group
Pike et al., (1981) 1972-8 P USA < 33 163 3.5t > 8 yrs Before FFTP
Pike et al., (1983) 1972-82 P USA < 37 314 4.9t > 6 yrs Before 25
Vessey et al., (1982, 1983) 1968-80 H UK < 36 210 1.0 > 8 yrs Ever
0.6 > 4 yrs Before FFTP
McPherson et al., (1987) 1980-4 H UK < 45 351 2.6t > 4 yrs Before FFTP
Rosenberg et al., (1984) 1976-81 H USA 20-29 29 0.9 Ever
30-39 188 5.0* > 5 yrs 10 yrs ago
Miller et al., (1986) 1977-83 H USA <45 521 0.9 Ever
1.4 >7 yrs Before FFTP
Miller et al., (1989) 1983-6 H USA 25-44 407 4.1* > 10 yrs Ever
Stadel et al., (1985) 1980-2 P USA < 45 2088 1.2 > 4 yrs Before FFTP
Stadel et al., (1989) 2.7* > 12 yrs Before FFTP
Paul et al., (1986) 1983-5 P NZ 25-34 42 4.6 > 10 yrs Ever
Meirik et al. (1986) 1984-5 P Sweden & <45 422 2.2t > 12 yrs Ever
Norway
Jick et al. (1989) 1975-83 H USA <43 127 1.4 > 10 yrs Ever
UK National
Case-Control Study
Group (1989) 1982-5 P UK < 36 755 1.7t > 8 yrs Ever
WHO (1990) 1979-84 H Many < 35 301 1.3 Ever
*P< 0.05. tP < 0.05 fortrend withdurationoforalcontraceptive use. aRelative risk forsubgroup orlongest duration ofusegroup as
described in final column. FFTP = first full-term pregnancy.
National Case-Control Study Group (1989). In addition Paul et al. (1986) and the World Health Organization Study
(WHO, 1990) reported increased risks that were not statistically significant. Rosenberg et al. (1984) and Miller et al. (1989)
found some exposure groups to be at increased risk but no increasing trends in risk with increasing duration of use. These
two studies and that of Miller et al. (1986) were carried out by the same investigators under similar conditions, and the
lack of consensus between them is certainly not suggestive of a strong effect.
Until recently the apparent lack of any effect in the large and well conducted CASH study (Stadel et al., 1985) was
extremely influential in the overall interpretation of the published studies. The recent re-analyses suggesting an effect
before first full-term pregnancy (Peto, 1989; Stadel et al., 1989) and the recent report of the UK National Study (UK
National Case-Control Study Group, 1989) suggesting an effect of total use do now suggest that there is an increased
risk of breast cancer in young women associated with oral contraceptive use. The four most recently reported
population-based case-control studies (Paul et al., 1986; Meirik et al., 1986; UK National Case-Control Study Group,
1989; Stadel et al., 1989) are thus consistent with each other in finding an association between oral contraceptive use
and breast cancer risk in young women although the relative risks reported by Paul et al. (1986), based on only 42
women aged under 35, did not reach statistical significance. The question of timing of use is more difficult and the
evidence at present for an effect before first full-term pregnancy rather than for total use is inconclusive.
If the association between oral contraceptive use and breast cancer risk is causal then a dose-response relationship
should beapparent. Thesimplestmeasureofdose, orexposure, isduration ofuse, and infiveofthepositivestudies(Pikeet
al., 1981, 1983; Meirik et al., 1986; McPherson et al., 1987; UK National Case-Control Study Group, 1989) there was
evidence ofa significant trend in risk with increasingyearsofuse. Some authors have attempted to quantifyexposure in a
morespecific way by recording oralcontraceptive brand and bycalculating risks associated with differentpreparations or
formulations. The CASH Study Group (Centres for Disease Control and National Institute ofChild Health and Human
Development, 1986) were able to examine risks in women who had used exclusively one brand oforal contraceptive, but
none ofthe formulations examined was associated with an elevated risk ofbreast cancer (which may not be surprising in
viewofthenegativefindingsofthestudywhenallwomenuptoage54wereincluded). Milleretal. (1989)alsoexamined the
effect ofdifferent brands, although not in the context ofexclusive use, and also found no evidence ofan effect associated
with anyparticularformulation. ThedataofMcPhersonetal. (1987)suggested thatusebeforefirstfull-term pregnancy of
preparations marketed before the early 1970s containing ethinyl oestradiol was associated with an elevated breast cancer
risk, butJick etal. (1989)rankedoralcontraceptive brandsin the samewayand failed tofindanyeffect. The UK National
Case-Control Study Group (1989) examined theeffect ofdifferent formulations according to theircontent ofoestrogen.
Relative risks were significantly higher for preparations containing at least 50jsg oestrogen compared with lower dose
combined oral contraceptives. Data for progestogen only pills appeared to show a marginally protective effect for more
than 1 year's use, but the number ofwomenexposed for this length oftimewasvery small. Attempts to rank thedifferent
progestogens contained in combined oral contraceptives have not so far been successful. There is thus no very good
evidence that any particular dose or combinations of oestrogen or progestogen are especially harmful. There is some
indication, however, intwostudies, that thepreparations thatweremarketed inthe 1960sandearly 1970swhichcontained
higher doses of oestrogen may be more harmful than the modern pills containing lower doses of oestrogen.
One ofthedifficulties incomparing andcontrasting the studies lies in thedifferences indesign and methods ofanalysis.
At a recentmeeting attheRoyalSocietyofMedicine(July 1989)thepossibilityofcollaborationbetweentheauthorsofthe
various studies wasdiscussed. Onewayforwardmight befortheseauthors to agree acommon setofanalysesand foreach
to carry out theseanalysis onhis orher owndata set. Such anapproachmighthelp to reconcile someoftheinconsistencies
between the studies.
Thepreceding discussion has been concerned with case-control studies. The two cohort studies carried out in the UK
do have some, very limited, data on young women. Some slight evidence in support of an association between oral
contraceptive use and breast cancer risk comes from the Royal College of General Practitioners' Study (Kay &
Hannaford, 1988) but any effect disappears after the age of35. The Oxford Family Planning Association cohort study4 C.E.D. CHILVERS & J.M. DEACON
(Vesseyetal., 1989)hasneversuggested anyassociation. Thewomenrecruitedforthesestudieswere,however, allmarried
and most were in their middle reproductive years at entry.
Although the cumulative evidence from case-control studies does now point to an increased risk of breast cancer
associated with oralcontraceptive use, thisevidenceisconfined to womendiagnosedwithbreastcancerataveryearlyage
(upto 35 or40)andwhohaveused oralcontraceptivesduringtheirlateteensandearly20s. Atpresentthereisnoevidence
that this riskpersistsafter age40, butnoris thereanyevidence thatit does notdo so. Itis simply too soon to tell. Thereis
certainly at present no evidence that women exposed to oral contraceptives only at older ages have any increased risk of
breast cancer. Thereis suggestiveevidence thattheepidemiology ofyoungbreastcancermaydifferfromthatatlaterages;
forexample, anumber ofrecent studies havesuggested thatbreastfeedingmayhaveaprotectiveeffectagainstdeveloping
breast canceratanearly age (Byers etal., 1985; McTiernan etal., 1986; UKNational Case-Control StudyGroup, 1989),
whereas aneffectinolderwomen has notgenerally been found. It is, therefore, conceivable thatanyincreased riskrelated
to oralcontraceptives mayapply only to womendiagnosed with breastcanceratyoungagesbut notto olderwomen. This
is suggested by the data from the Royal College of General Practitioners' study (Kay & Hannaford, 1988).
To put the whole question in perspective, the cumulative risk ofbreast cancer up to age 36 in the UK is 1 in 500. Data
from the UK National Study (UK National Case-Control Study Group, 1989) would suggest that even after 8 years of
oralcontraceptive usethis riskwould increase to onlyabout 1 in300. Thelife-time riskofbreastcancer, however, isabout
1 in 14; any increase in this risk would be ofmajorpublic health importance. Continuedvigilance ofthe cohort ofwomen
first exposed to oral contraceptives during their late teens and early 20s by means of future studies and monitoring of
incidence and mortality statistics is essential. The importance of timeliness and completeness of cancer registration
statistics in this country in this respect cannot be overemphasised.
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